An interventional study of ECMO in Acute Respiratory Distress Syndrome, sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-23.
Sponsored by University Hospital Tuebingen · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Respiratory Distress Syndrome with a site in Germany — 7 open to participants now, 8 under way, 1 of them phase 3. Respiratory Distress Syndrome · Germany.
Among the 48 studies in Respiratory Distress Syndrome with a site in Germany, this one is the 5th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2025, is one of 13 with no phase, and was the 26th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →7 of the 48 studies in Respiratory Distress Syndrome with a site in Germany are open now. Recruiting first, the newest first:
BioAegis Therapeutics Inc. · Sites in Germany, United States, Belgium and 10 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Germany, Switzerland
Ages 23 wk–31 wk
University Hospital Tuebingen · Sites in Germany
Ages 18+
AstraZeneca · Sites in Germany, United States, Argentina and 36 more countries
Ages 18+
CytoSorbents, Inc · Sites in Germany, Austria, Italy and 3 more countries
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 7
First in 2003; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 508 is above the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.
Median enrollment 114 across the 26 interventional studies, 132 across the 21 observational. Of the 28 that completed or were terminated, 4 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 48 have an industry lead sponsor. The 10 most frequent:
University Hospital Tuebingen is the lead sponsor of 492 studies on the registry; 110 are open to participants now.
University Hospital Tuebingen has 7 studies filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Respiratory Distress Syndrome with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05947955BioAegis Therapeutics Inc.Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS) | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 48 studies in Respiratory Distress Syndrome with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is a prospective randomized multicenter trial that assigns patients to either a treatment for Acute Respiratory Distress Syndrome (ARDS) with an Extracorporal Membrane Oxygenation (ECMO) immediately after admission to the intensive care unit or conservative treatment. The later can undergo ECMO following failure of conservative therapy as a rescue therapy. Patients will be included within 24 hours of the onset of symptoms of ARDS and will be randomized according to standard procedure. Follow-up will be performed until day 90 after study inclusion.
Patients suffering acute ARDS defined according to the Berlin Definition starting from severe stage with acute onset and (i) ratio partial arterial pressure of oxygen fraction of inspired oxygen inspired oxygen fraction (PaO2/ FiO2) ≤ 200 (ii) Bilateral opacities consistent with pulmonary edema on frontal chest radiograph, and (iii) requirement for positive pressure ventilation via an endotracheal tube or non-invasive ventilation (iv) no clinical evidence of left atrial hypertension, or if measured, a Pulmonary Arterial Wedge Pressure (PAOP) less than or equal to 18 mm Hg (v) less than 96 hours from onset of ARDS (vi) less than 7 days from the initiation of mechanical ventilation will be treated by ECMO either within 24 hours to referral to an ARDS ECMO center or as rescue therapy after failure of conventional therapy.
Outcome measures have been chosen according to robustness and sensitivity to change. They are of high clinical impact and reflect the treatment effect desired by clinicians.
Primary efficacy endpoint: All cause mortality by 90-days.
Key secondary endpoints are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
ECMO is placed immediately after admission to the intensive care unit
Device: ECMO
Conservative therapy unless failure of therapy.
ECMO implantation immediately after ICU admission
90 day all cause mortality
90 day all cause mortality
Time frame: 90 days after study inclusion
Sepsis-related organ failure assessment score (SOFA) Organ Failure Scores
SOFA Organ Failure Scores
Time frame: 1-14, 28 and 90 days after study inclusion
Duration of mechanical ventilation
Duration of mechanical ventilation
Time frame: within 90 days after study inclusion
28 day all cause mortality
28 day all cause mortality
Time frame: 28 days after study inclusion
ICU length of stay
overall length of stay on ICU
Time frame: overall length of stay
Started Mar 2025 (actual). Primary completion is estimated for Aug 2028, 41 months after the start.
Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 41 months is above that.
Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →
University Hospital Tuebingen →